Announcement PDF Emyria ASX Announcement | 29 April 2026 ASX RELEASE. 29 April 2026 Emyria Extends National Expansion into New South Wales Emyria partners with third independent Private Hospital Operator extending National Clinic Footprint. Key Highlights: • Matilda Nepean Private Hospital becomes third independent Private Hospital Operator to Partner with Emyria’s National Empax clinic network. Partnership provides entry into New South Wales, Australia’s most populous state. • Enhanced Footprint extends treatment bed capacity to 18. Four new treatment beds to be established in Sydney at Matilda Nepean Private Hospital, augmenting Emyria’s Perth,1,2 Brisbane3 and Mornington Peninsula4 locations. New clinic commencement targeted for Q3 CY2026. • Creates a presence in every major East and West Coast State. Five sites across Western Australia, Queensland, Victoria and New South Wales, covering Australia’s four most populous jurisdictions. • New South Wales clinical workforce recruitment already underway.5 Pro-actively accelerating operationalisation of the New South Wales site. • Psychiatrists and Authorised Prescriber numbers growing. Six new Authorised Prescriber (AP) approvals received from the Regulator, growing AP network from 6 to 12. New AP approvals to support Perth, Brisbane and Mornington Peninsula clinics. Seven psychiatrists due to attend New South Wales training. • Strengthens the Empax Global Partnership Program Offering.6 Broadens geographic reach for International Drug Sponsors and clinical trial partners per the Company’s 20 April 2026 announcement. Emyria Limited (ASX: EMD) (“Emyria”, or the “Company”), a leader in innovative mental health treatments, is pleased to announce an Agreement with Matilda Healthcare to establish a further Empax clinic in New South Wales. Matilda Healthcare, Western Sydney and Regional New South Wales Matilda Nepean Private Hospital is a licensed private hospital in Kingswood, New South Wales. Empax will establish a dedicated 4-room clinic to deliver its mental health treatment programs targeted to commence around Q3, CY2026, assuming all necessary regulatory approvals are in place. The Kingswood location was selected for its strategic reach and modern facilities. Beyond the immediate Western Sydney catchment of more than 2.5 million people, it serves as a critical access point for patients across the broader North West New South Wales region, including Dubbo, Orange, Bathurst, Tamworth and Mudgee, complementing existing specialist trauma and mood disorder services. ASX RELEASE Emyria ASX Announcement | 29 April 2026 2 National Empax Network The addition of a clinic at Matilda Nepean Private Hospital will expand the Empax network to five locations across four jurisdictions. Importantly, this partnership with a further, new hospital operator demonstrates Emyria’s growing reputation as a leader in the development of complex mental health treatments. Site Jurisdiction Status Perth (x2 centres) Western Australia Operating Brisbane (Avive) Queensland Operating Mornington Peninsula Victoria Operational Q2 CY26 Matilda Healthcare, Kingswood New South Wales Term sheet executed This network provides Emyria national scale, accelerates real-world data collection and also underpins the clinical infrastructure for the newly announced Empax Global Partnership Program6 . Authorised Prescriber growth The growing cohort of approved AP’s demonstrates psychiatrist acceptance of and support for the Empax clinical network, governance and infrastructure. Approved AP numbers have doubled with six new Empax trained Psychiatrists recently receiving AP approval, increasing the total from six to 12. New AP approvals will support the Perth, Brisbane and Mornington Peninsula clinics. A further eight psychiatrists are expected to attend New South Wales Empax training in June to support their Authorised Prescriber applications. Executive Chair Greg Hutchinson commented: “Establishing an Empax clinic in New South Wales provides Emyria a presence in every major Australian State and Territory, and increases treatment room capacity to 18. Matilda Healthcare was selected for its strategic reach into Western Sydney and the underserved North West New South Wales region. Combined with the launch of the Empax Global Partnership Program and recent Authorised Prescriber approvals, this further expansion provides Emyria the national scale and clinical workforce to help deliver on our ambition to be the leading platform for advanced mental health therapies in Australia, and as a global partner for international drug development sponsors.” Key Terms: Initial term 3 years, with two further options to renew (subject to Emyria satisfying a minimum utilisation condition) Licence fee Payable on a monthly basis and based on a fee schedule reflecting increased rates in year 2. Exclusivity Exclusive rights for psychedelic-assisted therapy at the facility. First right of refusal for other Matilda sites. Operations Empax provides the clinical team and care model; Matilda provides dedicated licenced hospital space and infrastructure, Schedule 8 licensure, secure storage/drug management ASX RELEASE Emyria ASX Announcement | 29 April 2026 3 Binding terms Key commercial, confidentiality, exclusivity and financial provisions are binding. Formal licence agreement to follow The agreement remains subject to execution of a formal licence agreement, which the Company intends to negotiate as a priority. This release has been approved by the Board of Emyria. For further information, investment opportunities, or more about Emyria’s approach to mental health treatment, please contact: Greg Hutchinson Executive Chair 1300 436 363 | investors@emyria.com References: 1. See ASX release dated 10 April 2024 2. See ASX release dated 14 April 2025 3. See ASX release dated 13 August 2025 4. See ASX release dated 16 December 2025 5. See ASX release dated 2 April 2026 6. See ASX release dated 20 April 2026 ASX RELEASE Emyria ASX Announcement | 29 April 2026 4 CAUTIONARY NOTE ON FORWARD-LOOKING STATEMENTS Any statements in this press release about future expectations, plans and prospects for the Company, the Company’s strategy, future operations, and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company’s ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company’s ability to obtain marketing approvals for its product candidates. In addition, the forward-looking statements included in this press release represents the Company’s views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date hereof. Risks associated with the use of MDMA, MDMA-inspired compounds and psilocybin All medicines carry risks and specialist prescribers, such as registered psychiatrists, are best placed to assess the suitability of a new medication against a patient’s individual circumstances and medical history before proceeding. Adverse effects of MDMA include high blood pressure, increased pulse rate, faintness, and panic attacks, and in some rare cases it can cause loss of consciousness or trigger seizures. Other side effects include involuntary jaw clenching, decreased appetite, restless legs, nausea, headache, sweating and muscle/joint stiffness. Adverse effects of psilocybin can include temporary increase in blood pressure and a raised heart rate. There may be some risk of psychosis in predisposed individuals. The effects of MDMA and psilocybin are unlikely at low doses in the treatment regimens used in psychedelic-assisted psychotherapy while appropriately managed in a controlled environment with direct medical supervision. The risk profile of the MDMA inspired compounds is currently unknown. The availability of these products is subject to the safety and efficacy of the products being tested through clinical trials. Emyria makes no representations or warranties as to the safety or efficacy of the products or the products’ ability (or the ability of its key compounds) to be used in the treatment of indications such as PTSD. There are currently no approved products containing MDMA, psilocybin or MDMA inspired compounds that the TGA has evaluated for quality, safety and efficacy. Emyria Limited develops and delivers new treatments for mental health and select neurological conditions through an integrated model of direct clinical services and treatment development: Emyria Healthcare: Evidence-based treatment for patients not finding relief from conventional care while also helping evaluate emerging new therapies like assisted therapy for PTSD and assisted therapy for treatment-resistant depression. Emyria Data: Robust and ethically sourced Real-World Data gathered with patients to improve Emyria’s unique therapy and drug development programs. Emyria’s Pipeline: New psychedelic-assisted therapies and drug treatments for mental health and select neurological diseases. EMYRIA’S INTERACTIVE INVESTOR HUB Investorhub.emyria.com Interact with Emyria’s announcements and updates by asking questions and comments, which our team can respond to where possible. generates informs